iSpecimen to Participate in the ThinkEquity Conference on October 26, 2022

Lexington, Massachusetts--(Newsfile Corp. - October 18, 2022) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, Interim CEO and CFO of iSpecimen, will present at the ThinkEquity Conference to be held at the Mandarin Oriental Hotel in New York City on October 26, 2022 at 4:30 p.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with iSpecimen's management team, please contact your appropriate ThinkEquity representative, or send an email to KCSA Strategic Communications at [email protected].

About iSpecimen

iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss
[email protected]

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
[email protected]

###

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140932

You May Also Be Interested In

• C3 Metals Intersects 64.9 Metres at 3.45% Copper Equivalent, Including 23.3 Metres at 6.64% Copper Equivalent at its Khaleesi Project, Peru - Highest Grade Copper and Gold Mineralization Intersected t
• Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
• BRS Resources Approved to Commence Trading on the OTCQB Venture Market